Octagon Capital Advisors LP Apellis Pharmaceuticals, Inc. Transaction History

Octagon Capital Advisors LP

$307 Million
Q3 2025

A detailed history of Octagon Capital Advisors LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 903,500 shares of APLS stock, worth $18.4 Million. This represents 6.66% of its overall portfolio holdings.

Number of Shares

903,500

Previous 903,500 -0.0%

Holding current value

$18.4 Million

Previous $15.6 Million 30.74%

% of portfolio

6.66%

Previous 5.94%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$16.36 - $23.0 $19.5 Million - $27.4 Million	-1,190,500 Reduced 56.85%	903,500 $15.6 Million
Q1 2025 May 16, 2025	BUY	$21.87 - $34.63 $45.8 Million - $72.5 Million	2,094,000 New	2,094,000 $45.8 Million
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $3.64 Million - $5.19 Million	126,100 Added 4.38%	3,006,980 $86.7 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $2.81 Million - $4.41 Million	73,900 Added 2.63%	2,880,880 $111 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $7.01 Million - $12.2 Million	188,680 Added 7.21%	2,806,980 $168 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $48.4 Million - $58.9 Million	-631,700 Reduced 19.44%	2,618,300 $239 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $4.19 Million - $6.03 Million	90,000 Added 2.85%	3,250,000 $214 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $24.9 Million - $35.2 Million	576,941 Added 22.34%	3,160,000 $163 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $8.52 Million - $14.4 Million	243,000 Added 10.38%	2,583,059 $117 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $11.3 Million - $17.3 Million	319,148 Added 15.79%	2,340,059 $119 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $13.1 Million - $20.9 Million	425,000 Added 26.63%	2,020,911 $95.5 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $10.7 Million - $23.7 Million	339,646 Added 27.04%	1,595,911 $52.6 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $29 Million - $45.9 Million	707,891 Added 129.09%	1,256,265 $79.4 Million
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $16.9 Million - $31.4 Million	548,374 New	548,374 $31.4 Million

Others Institutions Holding APLS

# of Institutions

330

Shares Held

124M

Call Options Held

4.15M

Put Options Held

769K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Account

Octagon Capital Advisors LP Apellis Pharmaceuticals, Inc. Transaction History